Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in San Sebastian De Los Reyes – page 224

3 196 clinical trials in San Sebastian De Los Reyes, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
San Sebastian De Los Reyes at a glance
3 196
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 196 trials in San Sebastian De Los Reyes

Open in trial search

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Small cell lung cancer extensive stage

Not recruiting

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Endocrine ophthalmopathy

Not recruiting

Study of Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Psoriasis

Not recruiting

Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ovarian cancer recurrent

Not recruiting

Study on ADP-A2M4CD8 and Nivolumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:USWM Ct LLC

Colorectal cancer

Not recruiting

Study of Pembrolizumab and Olaparib for Patients with Advanced Colorectal Cancer with DNA Repair Deficiency

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Grupo Espanol Multidisciplinar En Cancer Digestivo

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Novartis Pharma AG

Neoplasm

Not recruiting

Study on CTL-002 and Nivolumab for Patients with Advanced-Stage, Relapsed/Refractory Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:CatalYm GmbH

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Breast cancer metastatic

Not recruiting

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in San Sebastian De Los Reyes

What the registry says about research in the country

01 Immunology & Allergies

Research focusing on innovative treatments for allergic rhinoconjunctivitis and immune system disorders. Studies include testing immunotherapy effectiveness using specific allergen proteins.

  • Allergic Rhinoconjunctivitis
  • Atopic Dermatitis
  • Myasthenia Gravis

Trials evaluate novel therapeutic approaches for autoimmune conditions and allergic responses.

02 Cardiovascular Health

Comprehensive studies addressing various cardiovascular conditions, including deep vein thrombosis and heart failure management.

  • Pulmonary Embolism
  • Atherosclerotic Disease
  • Hypercholesterolemia

Research focuses on innovative treatments and preventive approaches for cardiovascular complications.

03 Oncology Research

Advanced clinical trials investigating treatments for various cancer types, with emphasis on ovarian cancer and breast cancer therapies.

  • Epithelial Ovarian Cancer
  • HER2+ Breast Cancer
  • Endometrial Cancer

Studies evaluate targeted therapies and maintenance treatments for cancer patients.

04 Metabolic & Systemic Disorders

Research examining treatments for systemic lupus erythematosus and metabolic conditions affecting multiple body systems.

  • Obesity Management
  • Diabetic Neuropathy
  • Liver Disease

Trials focus on innovative therapeutic approaches for chronic systemic conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.